CMV pp65 Protein

<strong>CMV pp65 Protein</strong>_x000D_ <strong>Catalog number:</strong> B2011987_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 1-2 mg/mL_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20 °C_x000D_ <strong>Keywords:</strong> UL83 protein, Cytomegalovirus pp65 protein, Cytomegalovirus UL83 protein, CMV Pp65 protein, CMV Pp65 antigen_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Agnarsdóttir M, Popova S, Alafuzoff I. Expression of CMV protein pp65 in cutaneous malignant melanoma PLoS One. 2019 Oct 11;14(10):e0223854._x000D_ 2: John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw CA, Ciaramella G. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity Vaccine. 2018 Mar 14;36(12):1689-1699._x000D_ 3: McVoy MA. Cytomegalovirus vaccines Clin Infect Dis. 2013 Dec;57 Suppl 4(Suppl 4):S196-9._x000D_ 4: Tanaka N, Kimura H, Hoshino Y, Nishikawa K, Kojima S, Nishiyama Y, Morishima T. Expression of tegument protein pp65 of human cytomegalovirus (CMV) and its application to the analysis of viral-specific cellular immunity in CMV-infected individuals Arch Virol. 2002 Dec;147(12):2405-17._x000D_ 5: Iberer F, Tscheliessnigg KH, Halwachs G, Auer T, Wasler A, Petutschnigg B, Müller H, Freigassner M, Allmayr T, Hipmair G, et al. CMV antigenemia (the lower matrix protein_PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation Wien Klin Wochenschr. 1995;107(23):718-22._x000D_ 6: Li Pira G, Bottone L, Ivaldi F, Pelizzoli R, Bracci L, Lozzi L, Scarso L, Tripodi G, Manca F. Recognition of CMV pp65 protein antigen by human CD4 T-cell lines induced with an immunodominant peptide pool Hum Immunol. 2004 May;65(5):537-43._x000D_ 7: Provenzano M, Lim JB, Mocellin S, Monsurro V, Bettinotti M, Marincola FM, Stroncek DF. The matrix protein_pp65(341-350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele Transfusion. 2003 Nov;43(11):1567-74._x000D_ 8: López-Oliva MO, Martínez V, Rodríguez-Sanz A, Álvarez L, Santana MJ, Selgas R, Jiménez C, Bellón T. Pre-transplant assessment of pp65-specific CD4 T cell responses identifies CMV-seropositive patients treated with rATG at risk of late onset infection Clin Immunol. 2020 Feb;211:108329._x000D_ 9: Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C. The detection of CMV pp65 and IE1 in glioblastoma multiforme J Neurooncol. 2011 Jun;103(2):231-8._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/15514011">10: Trivedi D, Williams RY, O'Reilly RJ, Koehne G. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy Blood. 2005 Apr 1;105(7):2793-801. </a>_x000D_ _x000D_ <strong>Products Related to CMV_pp65 Protein can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>